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Using patients’ own knowledge of early
sensations and symptoms to develop an
interactive, individualized e-questionnaire
to facilitate early diagnosis of lung cancer
Adrian Levitsky1,2†, Britt-Marie Bernhardson1†, Ingela Henoch3, Maria Olin4, Karl Kölbeck4, Nadja Rystedt5,
Carol Tishelman1,6† and Lars E. Eriksson1,7,8*†
Abstract
Background: One reason for the often late diagnosis of lung cancer (LC) may be that potentially-indicative
sensations and symptoms are often diffuse, and may not be considered serious or urgent, making their
interpretation complicated. However, with only a few exceptions, efforts to use people’s own in-depth knowledge
about prodromal bodily experiences has been a missing link in efforts to facilitate early LC diagnosis. In this study,
we describe and discuss facilitators and challenges in our process of developing and initial testing an interactive,
self-completion e-questionnaire based on patient descriptions of experienced prodromal sensations and symptoms,
to support early identification of lung cancer (LC).
Methods: E-questionnaire items were derived from in-depth, detailed explorative interviews with individuals
undergoing investigation for suspected LC. The descriptors of sensations/symptoms and the background items
obtained were the basis for developing an interactive, individualized instrument, PEX-LC, which was refined for
usability through think-aloud and other interviews with patients, members of the public, and clinical staff.
Results: Major challenges in the process of developing PEX-LC related to collaboration among many actors, and
design/user interface problems including technical issues. Most problems identified through the think-aloud
interviews related to design/user interface problems and technical issues rather than content, for example we re-
ordered questions to be in line with patients’ chronological, rather than retrospective, descriptions of their
experiences. PEX-LC was developed into a final e-questionnaire on a touch-screen smart tablet with one
background module covering sociodemographic characteristics, 10 interactive, individualized modules covering
early sensations and symptoms, and a 12th assessing current symptoms.
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Conclusions: Close collaboration with patients throughout the process was intrinsic for developing PEX-LC.
Similarly, we recognized the extent to which clinicians and technical experts were also important in this process.
Similar endeavors should assure all necessary competence is included in the core research team, to facilitate timely
progress. Our experiences developing PEX-LC combined with new empirical research suggest that this
individualized, interactive e-questionnaire, developed through systematizing patients’ own formulations of their
prodromal symptom experiences, is both feasible for use and has potential value in the intended group.
Keywords: Lung cancer, Respiratory diseases, Think-aloud interviews, Instrument development, Questionnaire
design, E-questionnaire, Internet, Usability, Tablet computers, User-computer interface
Background
Lung cancer (LC) accounts for nearly 1/5th of the
world’s estimated cancer-related deaths, as most individ-
uals are diagnosed in advanced stages [1, 2]. One reason
may be that sensations and symptoms potentially associ-
ated with LC are often diffuse [3–5] and expressed
through a variety of words, thus complicating interpret-
ation [4]. A wide range of diffusely formulated sensa-
tions and symptoms may delay care, as many might not
be considered serious or urgent [3–5]. However, with
only a few notable exceptions [5, 6], efforts to use peo-
ple’s own in-depth knowledge about prodromal bodily
experiences is a missing link in efforts to facilitate early
LC diagnosis. One reason for this may be related to the
difficulties inherent in differentiating among the com-
plex clusters of often subtle sensations and symptoms
which may indicate not only LC, but also a wide range
of other conditions. In-depth descriptions of bodily ex-
periences that might potentially be associated with LC
are thus an important point of departure. Given the
breadth of possibilities that each person’s symptomatic
profile may provide, any initiative that seeks to
systematize this wide variation would need a carefully-
designed, user-friendly tool offering a wide range of
expressive capacity. Thus, after obtaining qualitative data
about early symptoms and sensations potentially associ-
ated with LC, the authors sought to develop a flexible,
detailed but clinically-applicable instrument, capable of
aiding in LC diagnostic investigation to fill this gap.
Pen and paper questionnaires were once praxis, how-
ever, e-questionnaires can in some cases be more feas-
ible today [7–9]. Paper questionnaires, for example,
require resources to transfer data to an electronic form
for analysis. Both forms can require several rounds of
testing and improvement, resulting in considerable time
constraints before being ready to use [7–10]. Both de-
mand a range of expertise for their design; they need to
be user-friendly, contextually valid and relevant, and
minimize participant burden as much as possible, while
maintaining reliability in collecting required information
[8]. However, while sharing some start-up challenges
with paper questionnaires, e-questionnaires have other
development costs, especially related to the IT compe-
tence needed to develop and maintain them and fix
technical errors. In clinical practice, especially for those
with an encumbering disease like LC, e-questionnaires
that can be individualized through interactivity may be
one way to minimize burden for patients [11].
We therefore designed an individualized, interactive e-
questionnaire for in-depth investigation of early experi-
ences of sensations and symptoms experienced by pa-
tients referred for suspected LC. The aim of this study is
thus to describe and discuss facilitators and challenges
we encountered in the process of developing and initial
testing of this e-questionnaire, with content based on
patients’ experiences, to facilitate future endeavors of
this sort.
Methods and results
This study was approved by the regional ethics board
(EPN: #2008/51–31/3; #2011/438–32). The project de-
rived from common interests shared with a UK research
group [4], but was itself an independent multi-regional
Swedish initiative led by nurse researchers. We worked
with key actors, including representatives from the
Swedish lung cancer patient association, clinical nursing
and medical staff, and statisticians/epidemiologists.
The full process of developing the Patient EXperience
of Bodily Changes for Lung Cancer (PEX-LC) e-
questionnaire included three rounds of think-aloud in-
terviews, illustrated in the flow chart, Fig. 1.
Phase I
At the onset of this project (Fig. 1), early descriptors of
sensations and symptoms were derived from explorative
interviews carried out in several regional Swedish
hospitals, with 60 patients undergoing evaluation for
suspected LC (subsequent diagnosis: LC = 31; not LC =
29). Participants were asked about precursors of their
present contact with the healthcare system and were
explicitly asked about the knowledge they have about
their own bodily experiences. We probed for in-depth
descriptions of those early sensations and symptoms pa-
tients recalled. These open, volunteered descriptions
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were complemented with questions checking the pres-
ence and descriptions of other well-known LC symp-
toms. Background information (i.e. sociodemographic
characteristics, smoking status, and comorbidities) was
also elicited. The interviews were audio-taped and tran-
scribed verbatim, and these data were analyzed induct-
ively using NVivo software. The nearly 300 descriptors
and background variables derived in this manner were
the foundation for the development of the PEX-LC e-
questionnaire.
To be able to individualize documentation of patients’
experiences of their own early sensations and symptoms,
we concluded that an interactive e-questionnaire would
need to be developed to allow each person to respond to
items tailored to and appropriate for their specific symp-
tomatic profile. The development of PEX-LC was made
possible through collaboration with IT consultants.
Prior to development of the first version of PEX-LC,
we used the wording from the interviewed individuals to
create descriptors of early sensations and symptoms. We
then initiated a process of meticulously merging descrip-
tors to create questionnaire items related to different
symptomatic areas. Challenges were encountered in the
merging process, as different individuals used different
words for similar phenomena (e.g. “in pain” vs. “hurt-
ing”); we therefore made efforts to differentiate between
potentially distinct sensation qualities and words used as
synonyms. Also, we were aware of the risk of removing a
rare symptom which might be highly predictive.
At this time, our intentions for the e-questionnaire
were to: 1) use patients’ wording for descriptors, consid-
ering potential regional/dialectical differences, 2) formu-
late as few relevant items as possible, tailored to the
individual to reduce the burden of responding to the
questionnaire, 3) begin by asking about the individual’s
current state of health, followed by items about the ini-
tial experience of the particular problem, 4) complement
these data with scale-based questions assessing current
symptom intensity, and 5) summarize questionnaire re-
sponses upon completion for clinical use. The merged
and reformulated descriptors and background variables
were presented to lung medical and nursing clinicians to
check face validity and get professional feedback.
Version 1 of PEX-LC
The first PEX-LC prototype was developed with IT con-
sultants according to the points outlined above and then
tested in 2011 with two purposefully-chosen individuals
known to the researchers, to obtain different types of
user feedback on PEX-LC’s feasibility and usability. One
individual was chosen from the general public, while the
other was a patient activist expert on IT usability. Their
responses confirmed our suspicion that Version 1 was
an excessively long questionnaire that required a more
feasible structure prior to use. As a result, the scale-
based questions assessing symptom intensity were re-
moved, as they were peripheral to our aim.
Phase II
As seen in Fig. 1’s overview, during Phase II the e-
questionnaire was tested and revised in three rounds of
think-aloud interviews [12, 13] for versions 2–4 of PEX-
LC, respectively. During this time contracted IT consul-
tants assisted with the development of PEX-LC, including
adapting layout and addressing technical issues through
several versions. Statisticians worked with the consultants
Fig. 1 Developing the Patient EXperience of Bodily Changes for Lung Cancer (PEX-LC) e-questionnaire
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to ensure the accessibility of relevant information in quan-
tifiable terms.
Version 2 of PEX-LC
Based on the feedback described above, a second version
of PEX-LC was developed and tested in a first round of
think-aloud interviews with six patients with LC.
The think-aloud technique entails one-to-one cogni-
tive interviewing during which participants are asked to
verbalize their thoughts and feelings as they complete
the questionnaire, to be able to gain insight into ideas,
interpretations and cognitive processes at play as they
arrive at a response. Think-aloud aims to ensure face
validity of a tool, as it can identify the extent to which
the instrument is understood as intended and help to re-
solve potential misunderstandings [13, 14]. It thus may
maximize the performance of the questionnaire through
a step-by-step quality check through the user’s verbal-
ized cognitive processes, i.e. how the user comprehends,
retrieves, judges, and responds to information [13]. Indi-
viduals were also asked to reflect during and after com-
pletion what they liked or disliked when using the e-
questionnaire. Brief probing questions were used con-
currently to better understand the basis for responses,
while distracting as little as possible to minimize task
flow disruption [12, 15].
A number of major problems related to content and
technical aspects became clear through these think-
aloud interviews. For example, those questions that were
unclearly phrased became more apparent. We noted
problems for patients in differentiating temporal aspects,
e.g. reporting having a symptom at present versus when
it first manifested. We rephrased these types of ques-
tions for the next version and emboldened the font to
help distinguish present versus earlier symptoms.
We also noted a technical problem on the timeline
used for patients to indicate when sensations and symp-
toms first began, which further compounded difficulties
in reporting temporal aspects. Even other technical is-
sues were found which led to a redesigning of PEX-LC,
requiring further collaboration with IT consultants.
Version 3 of PEX-LC
With the third version of PEX-LC, a new round of
think-aloud interviews was carried out with three pa-
tients with LC and two clinical staff. Both a laptop and
smart tablet version were tested in this round, leading to
a decision to use the questionnaire in tablet form as it
was both more user-friendly and easier to handle in the
clinical setting, regardless of patients’ computer experi-
ence. However, many usability issues, including technical
bugs, were still encountered. For example, respondents
still had difficulties in completing the questionnaire due
to technical layout problems. The temporal issue in
Version 2 had not been resolved; despite our efforts, it
was still difficult to distinguish current versus earlier
symptoms. The new tablet layout also led to confusion
between the answering field and the scrolling area.
As we resolved some issues, new problems became vis-
ible through the think-aloud interviews, i.e. lack of
consistency in response alternatives and highlighting
colors. We also noted the importance of appropriate lay-
out for users to be able to understand when additional
probing questions were linked to a specific descriptor.
When we tested PEX-LC in a relevant clinical setting,
we also encountered unexpected problems with hospital
internet access, which led to a need to test different
internet providers for the e-questionnaire, as hospital
data security and ethical guidelines precluded our con-
nection to the hospital network.
A number of important suggestions came from partici-
pants in the think-aloud interviews, e.g. adding a pro-
gress bar to PEX-LC to gauge remaining questions. An
introductory title and brief summary were also suggested
for the module overview page, for better orientation.
Overall, through this process, we were able to improve
usability through a more streamlined questionnaire with
better aesthetic appeal. However, several issues
highlighted led to a need for major technical reworking
and further instrument enhancement. There was a
change of IT consultants during this period, which led
to long delays and the need to reorient new individuals
to our underlying goals and the work to date. One new
IT consultant began to work in closer collaboration and
more proximity with the research group. This helped re-
solve issues in a more timely fashion, as longer distances
had created delays with continuity and distance could
hinder understanding.
In summary, based on the think-aloud interviews and
better contact with IT consultants, we undertook a
major rework of PEX-LC on several levels. We simplified
the layout through removal of redundant questions and
updated the Background module to include potentially
relevant comorbidities, as we recognized the difficulties
for patients in differentiating their experiences by diag-
nosis; we therefore needed more clarity about their full
situation. To further improve PEX-LC based on partici-
pants’ input, we discarded our original intention of hav-
ing a retrospective approach, first asking about current
state of health, followed by questions related to when
problems began. Instead, a chronological approach was
implemented as this seemed to fit better with partici-
pants’ ways of recalling; early sensations or symptoms
were now addressed first, followed by questions about
more recent changes in experienced phenomena.
We had also prepared the e-questionnaire to
summarize patients’ response profiles which would be
printed and made available for clinical staff, to facilitate
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communication about patients’ symptom experiences.
However, in addition to technical issues, we now found
that staff did not perceive the summary to be as relevant
as initially suggested, as they had begun to use an in-
ternal symptom questionnaire. We instead determined
in collaboration with clinicians to use an additional vali-
dated module focusing on current health. We tested sev-
eral and together chose the European Organization for
Research and Treatment of Cancer Quality of Life Core
Questionnaire (EORTC-QLQ-C30) [16] as a 12th mod-
ule in PEX-LC.
At this point, we began to hold more frequent joint
meetings of the research group and clinicians at the lung
medicine department, to begin further planning and
protocol development for pre-diagnostic recruitment for
a later clinical study with PEX-LC. A nurse researcher
working at the lung medicine department was hired, to
facilitate closer collaboration with the clinical setting.
Version 4 of PEX-LC
The last round of think-aloud interviews was carried out
with eight patients with LC, testing the fourth version of
PEX-LC. The interactivity of the e-questionnaire was en-
couraging and no further major reworking was deemed
necessary, as most issues appeared to have been success-
fully resolved. We also noted that the patients seemed to
have no trouble in selecting descriptors that suited their
individual experiences, which suggested that PEX-LC’s
content adequately reflected the target group’s sensa-
tions and symptoms.
Some minor issues, however, were still apparent. Prob-
lems with internet and mobile signals at the hospital
remained, and it was still necessary to use a mobile
internet connection due network issues beyond our con-
trol. Finally, problems with the amount of time required
to complete the questionnaire in a busy hospital setting
were noted as we began to develop the protocol for a
larger clinical study. Thus, in addition to fixing minor
bugs, instructions were adapted to optimize use of pa-
tients’ limited time.
Final version of PEX-LC
PEX-LC was developed into a final e-questionnaire with
12 interactive modules on a touch-screen smart tablet,
allowing assessment of a symptom from its’ first mani-
festation until present time.
Figure 2 illustrates the finalized interactive modular
overview of PEX-LC. A progress bar indicates number
and percentage of overall module completion, and com-
pleted modules are indicated with green check marks.
Information boxes for each module, when tapped, pro-
vide brief background information about the questions
in that module. Modules do not have to be completed
sequentially but can be responded to in the order the
participant chooses.
The final e-questionnaire, as shown in Fig. 2, includes
11 base modules: Background; Breathing Difficulties;
Cough; Phlegm/Expectorates; Pain/Aches/Discomfort;
Fatigue; Voice Changes; Appetite/Eating/Taste Changes;
Olfactory Changes; Fever/Chills/Sweating; and Other
Changes (e.g. general physical health, malaise) – with
the additional 12th module focusing on health status
during the past week. The 11 base modules contain a
total of 484 possible items, consisting of background
questions and in-depth descriptors of early sensations or
symptoms, including follow-up items. However, the e-
questionnaire is individualized in response to the partici-
pant’s particular state of health. Therefore, not all
follow-up questions are seen by each participant, as only
those questions which are relevant in relation to each in-
dividual’s previous response profile are shown.
Fig. 2 Finalized interactive modular overview of the Patient EXperience of Bodily Changes for Lung Cancer (PEX-LC) e-questionnaire
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Fig. 3 Cough module flow example from the Patient EXperience of Bodily Changes for Lung Cancer (PEX-LC) e-questionnaire
Fig. 4 Flow example of follow-up descriptors in the Patient EXperience of Bodily Changes for Lung Cancer (PEX-LC) e-questionnaire
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The interactivity of the e-questionnaire is illustrated in
Figs. 3 and 4 using an example from the Cough module.
The first question in Fig. 3 appears on the screen at the
start of the module. Should the user answer “Yes,” s/he
then progresses to the timeline bar, where the month
and year the sensations or symptoms first began can be
indicated. If the sensation first appeared over 2 years
ago, the user would type in the year it was first noticed.
The last image in Fig. 3 illustrates follow-up questions,
with several choices of descriptors possible. Figure 4
shows an example of the type of follow-up descriptors
which appear after some responses. Here, “It varied over
the day” was first selected, with the follow-up response,
“In the evening” chosen among several possible follow-
up descriptors. Note that follow-up descriptors are in-
dented for clarity on the e-questionnaire; the follow-up
descriptors (shown in gray) would not be seen unless the
original corresponding descriptor was chosen.
Discussion
In this article, we describe the development of an inter-
active e-questionnaire, PEX-LC, designed to aid in diag-
nostic investigation of early sensations and symptoms of
possible LC. Initial interviews with 60 patients under in-
vestigation for suspected LC gave rise to all descriptors
and most background variables in PEX-LC. Initially, to-
gether with the research team, IT consultants focused
on developing the technical aspects of the instrument in
relative isolation; however, during the development
process we recognized the importance of better integrat-
ing the IT consultants into the research team. A series
of think-aloud interviews led to the refinement of the e-
questionnaire through several versions and pointed to
the need for better integration of content and technical
aspects.
In accordance with our original intentions in develop-
ing PEX-LC, we maintained colloquial wording of
descriptors, and diminished participant burden by indi-
vidualizing interactivity, using as few relevant questions
as possible for each specific respondent. We, however,
adapted our original retrospective approach for several
reasons, most importantly that the think-aloud inter-
views made clear that people tend to think chronologic-
ally, rather than retrospectively. Thus, PEX-LC was re-
designed so that the earliest problems that surfaced were
first described, with further probing about later relevant
changes. Additionally, scale-based questions for symp-
tom intensity were removed after initial testing to avoid
overburdening users, and became superfluous as current
state of health was covered by PEX-LC’s follow-up ques-
tions and the EORTC-QLQ-C30, which also assesses
symptom intensity. Finally, the planned summary of the
questionnaire was omitted due to perceived lack of clin-
ical relevance.
Previous studies have identified several early LC-
associated signs and symptoms [5, 17–20], including
hemoptysis, dyspnea, cough, and/or weight loss, and in
some instances, changes in appetite [5, 17, 18] and fa-
tigue [5, 17], up to 2 years before diagnosis. While PEX-
LC also includes these symptoms, we are able to assess
them in depth with more detail, and they have been
complemented with less common symptoms. While all
data about patient experiences in these extant studies
are retrospective, most of them derive from general
medical records and/or were obtained post-diagnosis.
However, data from medical records means that patient
experiences are filtered by professionals, and knowledge
of diagnosis and treatment side-effects may create biases
in patient recall. To our knowledge, only one other study
surveyed individuals referred for LC investigation prior
to diagnosis as is intended with PEX-LC, in that case
using a brief questionnaire with 20 symptoms [6]. To
summarize, two unique features of PEX-LC are that all
descriptors are derived from open, detailed interviews
with patients about their experiences, and that this data
was obtained prior to rather than post-diagnosis.
Several key issues needed to be addressed before the
PEX-LC e-questionnaire could be used in clinical re-
search settings. The most substantial challenges encoun-
tered in developing PEX-LC are discussed below, and
were related to collaboration among actors in the devel-
opment process; design/user interface problems and
technical issues; and clinical usability.
Collaboration among actors in the development process
We collaborated with three main groups of actors in de-
veloping PEX-LC: patients, clinical staff, and IT consul-
tants. A major strength of the development process and
e-questionnaire itself is that patients and their know-
ledge about their own bodies and situation were crucial
throughout. This was facilitated through our long-term
contact with the Swedish LC patient association and
with different lung medicine hospital departments, and
by using think-aloud interviews. Patients willingly shared
their substantial knowledge about their experiences with
us, thus making PEX-LC more comprehensive and rele-
vant than instruments based only on professional per-
spectives. At no point in PEX-LC’s development did any
participant mention experiencing a sensation or symp-
tom not already included. We also received feedback
that each patient’s unique symptom profile could be
expressed through the available response options. The
comments and issues raised by patients were instead
most often related to the technical interface.
Through our collaboration with IT consultants, usabil-
ity and technical issues were eventually resolved,
although the e-questionnaire development took a con-
siderable length of time. The time taken to resolve
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technical issues was in part due to changes in IT consul-
tants, communication problems with consultants who
did not work closely with the research group, and to
some degree, a lack of relevant IT expertise among the
core research team, leading to our inability to adequately
anticipate and sometimes communicate our IT needs. A
major facilitator in finalizing PEX-LC was a closer—both
geographically and in terms of teamwork—collaboration
with the last IT consultant.
Collaboration with clinical staff was periodic through-
out the study. There was a need to maintain enthusiasm
in all stages of the development process, with continued
reaffirmation and contact. Occasional passive resistance
from staff and middle-managers, in different stages of
PEX-LC’s development, caused delays in implementing
decisions made in collaboration between senior clini-
cians/managers and researchers. To ensure the facilita-
tion of clinical collaboration on all levels, we began to
arrange regular meetings with clinical nursing staff, and
employed a clinical nurse in the team to facilitate con-
tact with the clinical staff and help carry out the study.
In retrospect, drawing from knowledge gained through
PEX-LC development, we suggest that similar processes
might be optimized if all types of stakeholders are active
in the research team from study conception.
Design/user interface problems and technical issues
Interface challenges were encountered throughout PEX-
LC’s development. In designing the earliest versions, we
did not recognize that ordering questions chronologic-
ally instead of retrospectively would be more in line with
natural thought processes. This points to the importance
of continual input from potential respondents in opti-
mizing usability. This input was also important in under-
standing and responding to a wide variety of technical
issues. Had we discussed the issues earlier, clinicians
might have made us cognizant of the ethical and legisla-
tive boundaries we later encountered, which limited
internet access in the intended setting for clinical re-
search. Better IT and design competence in the research
team might have helped heighten usability and resolve
technical issues and bugs in a timelier fashion. Again,
this motivates having a broader range of competencies
working together in a core team.
Clinical usability and validity
Lessons learned from the literature, including a prior
development study, demonstrated that a smart tablet e-
questionnaire was feasible for use in a palliative clinical
setting [21], which is a group with a profile relatively
similar to those individuals with potential LC who are
targeted by PEX-LC. Additional smart tablet question-
naire developments in health-burdened individuals in-
clude Smaradottir et al.’s [22] telemedicine application
to assess user-reported symptoms for individuals with
chronic obstructive pulmonary disease. As in our study,
they used think-aloud techniques. The design strengths
noted in both their instrument and PEX-LC were simi-
lar, e.g. appropriate color contrast and main screen
interactivity, as were challenges, e.g. the need to include
a progress bar and to resize touch buttons [22]. How-
ever, Smaradottir et al.’s [22] study used an instrument
with an interface that demanded more IT familiarity
from users. Nonetheless, the respondents who tested
that smart tablet questionnaire found it usable.
Despite the many issues made apparent through re-
peated rounds of think-aloud interviews regarding de-
sign and interface of our smart tablet e-questionnaire, in
its’ final, individualized form with a wide array of pos-
sible descriptors, PEX-LC was able to be successfully im-
plemented in a large-scale clinical study with data
collected from 670 patients undergoing diagnostic work-
up for potential LC [23]. Despite the heavily health-
burdened users in this group, who are often considered
difficult to recruit, there was a high level of participation,
suggesting perceived relevance for patients.
The inductive approach that gave rise to a breadth of
individualized descriptors of PEX-LC managed to reflect
the clinical complexities often leading to late diagnosis.
Inclusion of the wide variety of early, pre-diagnostic pa-
tient symptom experiences allowed us to filter out and,
using machine learning, determine predictors of primary
LC based on data from a large subset of our cohort (506
individuals) [23]. We were able to identify 63 early
symptoms and sensations and seven background
variables in PEX-LC that were key to predicting primary
LC. It is, however, important to continue to test the in-
strument in a larger general population to determine if
the same variables are identified. It is promising that
recently-published follow-up results from the nationwide
population-based Danish Symptom Cohort [24], present-
ing a short set of nine investigated potential lung cancer
alarm symptoms among 37,455 randomly-selected eli-
gible individuals aged ≥40 [25] confirmed and cited
some of our key identified LC risk symptoms and sensa-
tions, most notably appetite loss. These confirmatory
findings are thus one step forward in confirming the
general validity of PEX-LC. Better determination of
PEX-LC’s clinical validity is however, also needed if we
are to flag patients in time for early diagnostic workup.
Another issue for continued research is testing against
other questionnaires to examine if PEX-LC provides data
beyond that of other self-report instruments. Our
intention was that PEX-LC would add granularity and
nuance to self-reported data about symptom experiences
beyond that generally assessed by less comprehensive
questionnaires. We have plans to test PEX-LC against
other existing instruments, however, some challenges in
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such comparison should be recognized. These include
different timeframes, formulation of questions and
symptoms assessed. However, a major challenge for
comparison is that the interactive nature of PEX-LC
means that the battery of questions answered differs by
participant whereas it is constant in other instruments.
Conclusions
In summary, close collaboration with patients through-
out the process was intrinsic for developing PEX-LC.
Similarly, we recognized the extent to which clinicians
and technical experts were also important in this
process. Similar endeavors should assure all necessary
competence is included in the core research team, to fa-
cilitate timely progress. Both the experiences detailed in
existing literature and our own experiences in develop-
ing and later successfully testing PEX-LC in our large
clinical cohort suggest that this individualized and inter-
active e-questionnaire, developed through systematizing
patients’ own formulations of their prodromal symptom
experiences, is feasible for use in the intended group.
PEX-LC has potential to provide an important com-
plement to other LC questionnaires, which are generally
intended to assess current status, typically after diagno-
sis, by assessing early sensations and symptoms prior to
diagnosis, while not affected by treatment. If its’ poten-
tial is realized after further testing for generalizability, it
might provide new data to contribute to shortened time
spans to LC diagnosis.
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